Skip to main content

Table 3 Clinical Features of patients with Kawasaki Disease presenting with obstructive jaundice

From: Hepatic predominant presentation of Kawasaki disease in adolescence case report and review of literature

Reference Age Hepato-megaly Icterus Abdominal Pain Serum ALT(x ULN) Serum AST(x ULN) Serum ALP(x ULN) Serum GGT(x ULN) Serum Bilirubin(umol/L) Pulmo-nary Involvement Treatment
Our patient 16 + + + 5.3 4.66 1.58 3.1 163 + IVIG 2 g/kg in divided doses of 0.8 g/kg on the first day and 1.2 g/kg on the second day.
Oral Aspirin. Refractory Disease requiring a further 1 g/kg of IVIG over 2 days.
Bader-Meunier et al. [17] 3.5 + + NR 5 2.5 4 15 23.9 IVIG 1 g/kg/day. Not refractory
Keeling et al. [18] 12 + + + 1.91 0.80 1.43 2.63 48.9 IVIG 1.6 g/kg/day.
Oral Aspirin.
Not refractory
McMahon et al. [19] 20 NR + + 4.74 2.28 1.83 4.45 134.4 IVIG 2 g/kg/day. Oral Aspirin. Not Refractory.
Valentini et al. [20] 6 NR + + 9.96 11.87 1 10.88 121.4 IVIG 2 g/kg/day. Oral Aspirin. Not Refractory.
Vázquez et al. [21] 6 + + NR NR NR 3.21 4.02 98.3 IVIG 2 g/kg/day. Refractory Disease requiring further IVIG 72 h after the 1st dose and 48 h of Methylprednisolone 15-30 mg/kg for 2 days.
Oral Aspirin.
  1. NR Not recorded, ULN Upper Limit of Normal